Vulpes Bio

1/ I’m SHORT $DNLI. They filed a safety study as their pivotal trial in the BLA. This application relies entirely on the clinical assumption that the FDA employs morons who treat uncontrolled substrate shifts like stone tablets from God.

$TERN down on news that $MRK bought a chinese obesity asset. Stock price once again improving (going lower) as if its obesity asset drives the co's value. You love to see it -- if you believe the TKI (validated MOA, possible BIC) is what's valuable

most people have no idea how fast we're moving by end of 2026, we will have > trials 10x cheaper(gingko x gpt already doing this) >peptide supply chain infrastructure(we're funding) >decentralized clinical trial platforms >gene therapy manufacturing at scale the biotech infrastructure unlock is happening brace for human 2.0.

Can someone explain to me why a CML patient would use $TERN?

Jensen Huang just called the exact top of the pharmaceutical industry. Not a pivot. Not a disruption. An extinction event. Huang: “Where do I think the next amazing revolution is going to come? And this is going to be flat out one of the biggest ones ever. There’s no question that digital biology is going to be it.” The medical establishment has spent centuries playing a chaotic game of trial and error. We’re about to mathematically engineer the human operating system. Huang: “For the very first time in human history, biology has the opportunity to be engineering, not science. When something becomes engineering, not science, it becomes less sporadic and exponentially improving.” Biology is no longer the dark art of random discovery. It’s a predictable, compounding execution loop. Translate the chaotic variables of chemistry into the laws of computer science and you stop waiting for accidental breakthroughs. You simply compute the cure. That line should terrify every pharmaceutical executive alive. Huang: “It can compound on the benefits of the previous years. And every researcher’s contributions compound on each other.” For decades, drug discovery has been an isolated, artisanal process. One lab. One team. One molecule. Years of blind iteration. The algorithm just shattered that entire bottleneck. Every failed protein fold, every successful synthetic molecule instantly trains the foundational model. Makes the next iteration mathematically smarter. Huang: “We’re going to have incredible tools that bring the world of biology, which is very chaotic and constantly changing and diverse and complex, into the world of computer science. And that is going to be profound.” Incumbent pharma looks at the human body and sees an unmanageable wall of variables. Engineers look at that exact same body and see raw data waiting to be compiled. No longer guessing how a molecule will react in the physical world. Running millions of zero-cost simulated iterations before a single test tube is ever touched. Rip the chaotic friction out of the physical lab and drop it directly into a massive GPU cluster? The timeline to map, edit, and optimize the biological machine doesn’t shrink. It collapses.

PSILOCYBIN BEATS NICOTINE PATCHES IN QUITTING SMOKING A study published in JAMA Network Open found a single dose of psilocybin—the active compound in psychedelic mushrooms—was far more effective than nicotine patches at helping smokers quit. In a trial of 82 adults, over 40% of participants who received psilocybin were smoke-free after six months, compared with about 10% using nicotine patches, with both groups receiving therapy. Lead researcher Matthew Johnson of Johns Hopkins University said the drug may help by altering brain communication and self-perception, potentially breaking addictive patterns. The findings add momentum to growing research into psychedelic-assisted treatments, though larger trials are still needed.